Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

NCT01732107 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Development of dovitinib was stopped.

Conditions

Bladder Cancer

Interventions

DRUG: Dovitinib

Sponsor

Noah Hahn, M.D.

Collaborators

[object Object]
[object Object]